Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy L Diamond

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Nucleic Acids Research|November 7, 2006
Role of metal ions in catalysis by HIV integrase analyzed using a quantitative PCR disintegration assayTracy L Diamond, Frederic D Bushman
Journal of Virology|November 25, 2005
Division of labor within human immunodeficiency virus integrase complexes: determinants of catalysis and target DNA captureTracy L Diamond, Frederic D Bushman
Biochemistry|May 5, 2009
Mechanistic variations among reverse transcriptases of simian immunodeficiency virus variants isolated from African green monkeysMark Skasko, Tracy L Diamond, Baek Kim
Human Gene Therapy|September 16, 2006
Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered tethering factorAngela Ciuffi, Tracy L Diamond, Young Hwang, et al.
The Journal of Biological Chemistry|May 13, 2003
Mechanistic understanding of an altered fidelity simian immunodeficiency virus reverse transcriptase mutation, V148I, identified in a pig-tailed macaqueTracy L Diamond, George Souroullas, Kellie K Weiss, et al.
The Journal of Infectious Diseases|June 10, 2024
Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir ProphylaxisJulie M Strizki, Tracy L Diamond, Valerie L Teal, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2024
No antagonism or cross-resistance and a high barrier to the emergence of resistance <i>in vitro</i> for the combination of islatravir and lenacapavirTracy L Diamond, Shih Lin Goh, Winnie Ngo, et al.
Antimicrobial Agents and Chemotherapy|May 12, 2022
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Tracy L Diamond, Winnie Ngo, Min Xu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 26, 2026
Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 WeeksLaurie A VanderVeen, Lisa Selzer, Silvia Chang, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2022
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to ResistanceMing-Tain Lai, Meizhen Feng, Min Xu, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Nucleic Acids Research|November 7, 2006
Role of metal ions in catalysis by HIV integrase analyzed using a quantitative PCR disintegration assayTracy L Diamond, Frederic D Bushman
Journal of Virology|November 25, 2005
Division of labor within human immunodeficiency virus integrase complexes: determinants of catalysis and target DNA captureTracy L Diamond, Frederic D Bushman
Biochemistry|May 5, 2009
Mechanistic variations among reverse transcriptases of simian immunodeficiency virus variants isolated from African green monkeysMark Skasko, Tracy L Diamond, Baek Kim
Human Gene Therapy|September 16, 2006
Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered tethering factorAngela Ciuffi, Tracy L Diamond, Young Hwang, et al.
The Journal of Biological Chemistry|May 13, 2003
Mechanistic understanding of an altered fidelity simian immunodeficiency virus reverse transcriptase mutation, V148I, identified in a pig-tailed macaqueTracy L Diamond, George Souroullas, Kellie K Weiss, et al.
The Journal of Infectious Diseases|June 10, 2024
Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir ProphylaxisJulie M Strizki, Tracy L Diamond, Valerie L Teal, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2024
No antagonism or cross-resistance and a high barrier to the emergence of resistance <i>in vitro</i> for the combination of islatravir and lenacapavirTracy L Diamond, Shih Lin Goh, Winnie Ngo, et al.
Antimicrobial Agents and Chemotherapy|May 12, 2022
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Tracy L Diamond, Winnie Ngo, Min Xu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 26, 2026
Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 WeeksLaurie A VanderVeen, Lisa Selzer, Silvia Chang, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2022
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to ResistanceMing-Tain Lai, Meizhen Feng, Min Xu, et al.
Pageof 3